Selling a Dental Practice to an Associate vs. a DSO (2026)
Selling to an associate gives you a simpler deal, more cash certainty, a shorter transition (60-120 days), and preserved practice culture, but usually at 70-80% of fair market value with seller financing.
Selling to a DSO gives you a higher headline multiple (5x-11x EBITDA) and possible second-bite equity upside, but with 60-80% cash at close, a 3-5 year employment commitment, compensation cut to associate rates, and complex earnout and rollover terms.
The right answer depends on your retirement timeline and how much you value certainty over upside.
This guide compares both paths in detail. For what DSOs actually pay, see our DSO acquisition offers guide, and for the underlying numbers, our dental practice valuation guide. Pennsylvania sellers should also review our Pennsylvania dental practice sale guide for DEA, Medicaid re-enrollment, and bulk sales requirements.
Selling to an Associate: How It Works
An associate buy-in (or buyout) is the traditional dental succession path: you sell the practice to a dentist already working for you, or to an outside individual dentist, typically financed through the SBA or seller financing.
The Economics
Price: Associate buyouts typically occur at 70-80% of fair market value. Individual buyers underwrite on SDE and often pay 60-80% of collections.
Structure: Usually SBA financing for 60-80% of the purchase price, or seller financing over 5-10 years. Seller financing provides steady income but carries collection risk.
Cash certainty: Higher proportion of guaranteed value than a DSO deal. No large rollover-equity component sitting illiquid for years.
The Advantages
- Simpler transaction: fewer contingencies, less complex legal structure
- Faster close: often 60-120 days
- Shorter transition: 30-90 days, not 3-5 years
- Preserved autonomy and culture: the buyer typically shares your clinical philosophy and keeps your team
- No earnout or rollover risk: you avoid performance-contingent payments and illiquid equity
The Tradeoffs
- Lower headline price than a DSO would offer for a qualifying practice
- Financing risk: the deal depends on the associate qualifying for SBA debt or you carrying the note
- Collection risk if you seller-finance
- Limited buyer pool: finding the right individual dentist takes time
Selling to a DSO: How It Works
A DSO (Dental Support Organization) is a PE-backed entity that acquires practices and takes over all non-clinical operations.
You sell to an organization, not an individual.
The Economics
Price: 5x-8x EBITDA for single-location general practices, 8x-11x for multi-location groups, 10x-14x+ for specialty. Higher headline value than an associate sale for practices that qualify.
Structure: 60-80% cash at close, 15-40% rollover equity in the DSO parent, the rest in earnouts over 12-36 months.
Compensation shift: You stay on as a clinical associate at 25-30% of collections, down from owner distributions.
The Advantages
- Higher headline multiple for qualifying practices
- Operational relief: the DSO takes over HR, billing, marketing, procurement, compliance
- Second-bite potential: rollover equity can pay out at the DSO’s next recapitalization
- Continue practicing clinically without the management burden
The Tradeoffs
- Only 60-80% is cash at close; the rest is contingent or illiquid
- 3-5 year employment commitment (7-10 years for some specialties)
- Compensation cut to associate rates
- Loss of operational autonomy and potential culture misalignment
- Earnout risk and illiquid, forfeitable rollover equity
Side-by-Side: Associate vs. DSO
Headline price: Associate 70-80% of FMV. DSO 5x-11x EBITDA (often higher for qualifying practices).
Earnings metric: Associate buyer uses SDE. DSO uses normalized EBITDA.
Cash at close: Associate higher proportion guaranteed (often via SBA). DSO 60-80%.
Transition period: Associate 30-120 days. DSO 3-5 years (7-10 for some specialties).
Post-sale role: Associate you exit. DSO you stay as a clinical associate at 25-30% of collections.
Autonomy: Associate preserved. DSO non-clinical control shifts to the organization.
Deal complexity: Associate simpler. DSO document-heavy with earnouts, rollover, employment, and non-compete.
Second bite: Associate none. DSO rollover equity (illiquid 5-7 years).
Best retirement timeline: Associate 1-2 years out. DSO 5+ years out.
| Associate Buyer | DSO Acquisition | |
|---|---|---|
| Multiple | Below market (3x–5x EBITDA) | 5x–12x EBITDA |
| Cash at close | 80–100% | 60–80% |
| Rollover / Earnout | Minimal | 15–30% rollover; 10–20% earnout |
| Timeline to close | 60–180 days | 3–9 months |
| Practice autonomy | Full — buyer runs it their way | Shared protocols, systems, branding |
| Second exit | No | Yes — rollover equity re-values at platform exit |
The $500K Question
For a typical $1.5M revenue practice, the value difference between a DSO sale and an independent exit can exceed $500,000. But the headline gap is misleading, because the DSO number includes contingent earnouts and illiquid rollover while the associate number is mostly guaranteed cash.
The honest comparison is expected realized value, not headline value. A 6x DSO multiple with earnouts and rollover can net less than an 8x independent sale once you risk-adjust the contingent components.
Many dentists default to a DSO without seriously running the associate numbers, and that is often a mistake.
Which Path Fits You
Sell to an Associate If You:
- Are 1-2 years from retirement and want a clean exit
- Run a sub-$1M EBITDA practice that won’t command premium DSO pricing
- Want full cash certainty without DSO equity exposure
- Care deeply about preserving your team and practice culture
- Have a capable associate ready to buy
Sell to a DSO If You:
- Have a $1M+ EBITDA practice with multiple associates and 2,000+ active patients
- Are willing to practice as an associate for 3-5 years post-close
- Want second-bite economics through rollover equity
- Have a retirement timeline 5+ years out
- Value operational relief from non-clinical management
The Hybrid Reality: Provider Concentration Decides a Lot
One factor quietly determines which path is even available: provider concentration. If you personally perform 90%+ of production, DSOs will either discount heavily (10-20%) or pass, because they can’t underwrite a practice that walks out the door with you.
That same practice may be a perfect associate sale, because an individual dentist is buying your chair.
Conversely, a practice with associate depth and 2,000+ active patients is exactly what DSOs want and may be underpriced in an associate sale. Knowing your concentration profile tells you which buyer pool will actually compete for your practice.
For more on how earnouts and rollover work in a DSO deal, see our guide to dental practice earnouts and equity rollovers.
Associate vs. DSO FAQ
Do DSOs pay more than associates for dental practices?
DSOs typically offer higher headline multiples (5x-11x EBITDA) than associate buyouts (70-80% of fair market value). But DSO deals structure 20-40% of value as contingent earnouts and illiquid rollover equity, while associate sales are mostly guaranteed cash. Risk-adjusted, the gap narrows and can reverse.
How long do I have to work after selling to a DSO vs. an associate?
DSO sales require a 3-5 year employment commitment (7-10 years for some specialties) as a clinical associate. Associate sales require only a 30-120 day transition, after which you can exit completely.
Which is simpler, an associate sale or a DSO sale?
An associate sale is significantly simpler: fewer contingencies, a faster close (60-120 days), and a straightforward financing structure. DSO deals are document-heavy with employment agreements, earnout provisions, rollover equity terms, and non-competes.
What size practice should consider a DSO over an associate sale?
DSO sales favor practices with $1M+ EBITDA, multiple associates, and 2,000+ active patients. Sub-$1M practices, especially owner-dependent ones, are often better served by an associate or individual-buyer sale that underwrites on SDE.
Can provider concentration affect which buyer I should target?
Yes. If you perform 90%+ of production, DSOs will discount 10-20% or pass entirely due to key-person risk, making an associate sale the more realistic path. Practices with associate depth are better positioned for DSO premiums.
Is seller financing common in associate sales?
Yes. Associate buyouts often use SBA financing for 60-80% of the price, or seller financing over 5-10 years. Seller financing provides steady income but carries collection risk if the associate underperforms.
How do I compare a DSO offer to an associate offer fairly?
Compare expected realized value, not headline value. Risk-adjust the DSO’s earnout (apply a realistic probability of hitting targets) and rollover (model the DSO’s exit prospects), then compare to the mostly-guaranteed associate proceeds. A free valuation establishes a realistic anchor before you weigh offers.